TACE versus TAE as therapy for hepatocellular carcinoma.
D000970:Antineoplastic Agents / Q000008:administration & dosage; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects; D006801:Humans; D008113:Liver Neoplasms / Q000628:therapy*; D012008:Recurrence; D015996:Survival Rate
D000970:Antineoplastic Agents